Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Autor: Noble F; Cancer Sciences Unit, University of Southampton, Southampton, UK., Lloyd MA; Cancer Sciences Unit, University of Southampton, Southampton, UK., Turkington R; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Griffiths E; Department of Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., O'Donovan M; Hutchison/Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK., O'Neill JR; Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK., Mercer S; Department of Surgery, Portsmouth NHS Trust, Portsmouth, UK., Parsons SL; Department of Surgery, Nottingham University Hospitals NHS Trust, Nottingham, UK., Fitzgerald RC; Hutchison/Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK., Underwood TJ; Cancer Sciences Unit, University of Southampton, Southampton, UK.
Jazyk: angličtina
Zdroj: The British journal of surgery [Br J Surg] 2017 Dec; Vol. 104 (13), pp. 1816-1828. Date of Electronic Publication: 2017 Sep 25.
DOI: 10.1002/bjs.10627
Abstrakt: Background: This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response to neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Methods: A questionnaire was distributed to 11 UK upper gastrointestinal cancer centres to determine the use of assessment of response to neoadjuvant chemotherapy. Records of consecutive patients undergoing oesophagogastric resection at seven centres between January 2000 and December 2013 were reviewed. Pathological response to neoadjuvant chemotherapy was assessed using the Mandard Tumour Regression Grade (TRG) and lymph node downstaging.
Results: TRG (8 of 11 centres) was the most widely used system to assess response to neoadjuvant chemotherapy, but there was discordance on how it was used in practice. Of 1392 patients, 1293 had TRG assessment; data were available for clinical and pathological nodal status (cN and pN) in 981 patients, and TRG, cN and pN in 885. There was a significant difference in survival between responders (TRG 1-2; median overall survival (OS) not reached) and non-responders (TRG 3-5; median OS 2·22 (95 per cent c.i. 1·94 to 2·51) years; P < 0·001); the hazard ratio was 2·46 (95 per cent c.i. 1·22 to 4·95; P = 0·012). Among local non-responders, the presence of lymph node downstaging was associated with significantly improved OS compared with that of patients without lymph node downstaging (median OS not reached versus 1·92 (1·68 to 2·16) years; P < 0·001).
Conclusion: A clinically meaningful local response to neoadjuvant chemotherapy was restricted to the small minority of patients (14·8 per cent) with TRG 1-2. Among local non-responders, a subset of patients (21·3 per cent) derived benefit from neoadjuvant chemotherapy by lymph node downstaging and their survival mirrored that of local responders.
(© 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.)
Databáze: MEDLINE
Externí odkaz: